Long-term control of T2-T3 rectal adenocarcinoma with radiotherapy alone

被引:73
作者
Gerard, JP
Chapet, O
Ramaioli, A
Romestaing, P
机构
[1] Ctr Antoine Lacassagne, Unite Biostat, F-06189 Nice 2, France
[2] Ctr Hosp Lyon Sud, Serv Radiotherapie Oncol, Lyon, France
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2002年 / 54卷 / 01期
关键词
rectal cancer; radiotherapy; local control;
D O I
10.1016/S0360-3016(02)02879-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To analyze the long-term result of patients presenting with T2-T3 rectal adenocarcinoma treated with curative intent by radiotherapy (RT) alone, using a combination of contact RT, external beam RT, and brachytherapy with an iridium implant. Patients were considered unsuitable for surgery because of the presence of severe comorbidity or because they did not consent to surgery and the possibility of a permanent stoma. Methods and Materials: Between 1986 and 1998, 63 patients (56 staged with endorectal ultrasonography) were entered into a pilot study. Patients had to have T2-T3, N0-N1, M0 adenocarcinoma of the middle or lower rectum involving less than two-thirds of the circumference. RT began with contact X-rays (80 Gy in 3 fractions for 21 days), followed by external beam RT (39 Gy in 13 fractions for 17 days) with a concomitant boost (4 Gy in 4 fractions). After a 4-6-week interval, an iridium implant delivered a completion dose of 20 Gy to the tumor. No chemotherapy was given. Results: The median age of the patients was 72 years. Of the 63 patients, 41 had T2 and 22 had T3 tumors. The mean distance of the tumor from the anal verge was 3.6 cm. All patients completed treatment according to the protocol, except for 7 for whom brachytherapy was not performed. With a median follow-up time of 54 months, the primary local tumor control rate was 63%; after salvage surgery, the ultimate pelvic control was 73% (46 of 63). The 5-year overall survival rate was 64.4%, and for 42 patients aged <80 years, it was 78% with 10 patients alive and well at ≥10 years. No severe Grade 3-4 toxicity was seen. Acute proctitis was seen in most patients but did not require treatment interruption. Late rectal bleeding occurred in 24 patients. Only 1 required blood transfusion. Good anorectal function was maintained in 92% of living patients. The T stage was a strong prognostic factor, with a 5-year overall survival rate of 84% and 53% for T2 and T3 lesions, respectively, in patients <80 years old. Conclusion: This is the first report of long-term local control and survival for ultrasound-staged T2-T3 rectal adenocarcinoma treated by RT alone, showing that high-dose irradiation to a small volume can provide a high therapeutic ratio for such tumors. (C) 2002 Elsevier Science Inc.
引用
收藏
页码:142 / 149
页数:8
相关论文
共 28 条
[1]   Selection criteria for treatment of rectal cancer with combined external and endocavitary radiation [J].
Birnbaum, EH ;
Ogunbiyi, OA ;
Gagliardi, G ;
Fry, RD ;
Myerson, RJ ;
Kodner, IJ ;
Fleshman, JW .
DISEASES OF THE COLON & RECTUM, 1999, 42 (06) :727-733
[2]  
DUTREIX A, 1982, DISOMETRIE CURIETHER
[3]   ASSESSMENT OF DEPTH OF INVASION IN RECTAL-CANCER BY ENDOSONOGRAPHY [J].
FEIFEL, G ;
HILDEBRANDT, U ;
DHOM, G .
ENDOSCOPY, 1987, 19 (02) :64-67
[4]   Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: The Lyon R90-01 randomized trial [J].
Francois, Y ;
Nemoz, CJ ;
Baulieux, J ;
Vignal, J ;
Grandjean, JP ;
Partensky, C ;
Souquet, JC ;
Adeleine, P ;
Gerard, JP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2396-2402
[5]   Addition of oxaliplatin to continuous fluorouracil, L-folinic acid, and concomitant radiotherapy in rectal cancer:: The Lyon R 97-03 Phase I trial [J].
Freyer, G ;
Bossard, N ;
Romestaing, P ;
Mornex, F ;
Chapet, O ;
Trillet-Lenoir, V ;
Gérard, JP .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (09) :2433-2438
[6]  
Gérard JP, 2000, GASTROEN CLIN BIOL, V24, P430
[7]   Combined curative radiation therapy alone in (T1) T2-3 rectal adenocarcinoma: A pilot study of 29 patients [J].
Gerard, JP ;
Roy, P ;
Coquard, R ;
Barbet, N ;
Romestaing, P ;
Ayzac, L ;
Ardiet, JM ;
Thalabard, JC .
RADIOTHERAPY AND ONCOLOGY, 1996, 38 (02) :131-137
[8]  
Gérard JP, 1999, ANN CHIR, V53, P1003
[9]   Endocavitary radiation therapy [J].
Gerard, JP ;
Romestaing, P ;
Ardiet, JM ;
Mornex, F .
SEMINARS IN RADIATION ONCOLOGY, 1998, 8 (01) :13-23
[10]  
HEALD RJ, 1998, ARCH SURG-CHICAGO, V133, P984